The upcoming presentation by Robert Hayes at the Protein Congress will address the targeting of intracellular proteins. Sounds promising but can we find a link to the collaborative work between Centyrex and the academic/biotech consortium described in the Janssen presentation of June 2013.
"Antibodies targeting intracellular oncogenic proteins can effectively be used to halt cancer growth in tumor-bearing mice, scientists claim."
The Janssen presentation of June 2013 discusses how bi-specific Centyrins inhibit the growth of tumor cells in a Xenograft model. More specifically, page 19 of the presentation which deals with the Intracellular Delivery of Centyrins, discusses selectivity and activity against intracellular kinases and IAPs. We have previously discussed IAPs refer my post of 28/12/2013; Inhibitors of Apoptosis Proteins - drugs in development that act as an inhibitor of apoptosis proteins are starting to show promise against this target.
Robert Hayes will discuss the targeting of intracellular proteins; what he will say I don't know but it would appear that it is one of the subjects being addressed by the academic/biotech consortium and their work with endosomal escape peptides.
PYC Price at posting:
1.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)